| アブストラクト | Fulvestrant, as the first selective estrogen receptor degrader, is widely used in the endocrine treatment of breast cancer. However, in the real world, there is a lack of relevant reports on adverse reaction data mining for fulvestrant. To perform data mining on adverse events (AEs) associated with fulvestrant and explore the risk factors contributing to severe AEs, providing a reference for the rational use of fulvestrant in clinical practice. Retrieved adverse event report information associated with fulvestrant from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database, covering the period from market introduction to September 30, 2023. Suspicious AEs were screened using the reporting odds ratio (ROR) and proportional reporting ratio methods based on disproportionality analysis. Univariate and multivariate logistic regression analyses were conducted on severe AEs to explore the risk factors associated with fulvestrant-induced severe AEs. A total of 6947 reports related to AEs associated with fulvestrant were obtained, including 5924 reports of severe AEs and 1023 reports of non-severe AEs. Using the disproportionality analysis method, a total of 210 valid AEs were identified for fulvestrant, with 45 AEs (21.43%) not listed in the product labeling, involving 11 systems and organs. The AEs associated with fulvestrant were sorted by frequency of occurrence, with neutropenia (325 cases) having the highest number of reports. By signal strength, injection site pruritus showed the strongest signal (ROR = 658.43). The results of the logistic regression analysis showed that concurrent use of medications with extremely high protein binding (>/= 98%) is an independent risk factor for severe AEs associated with fulvestrant. Age served as a protective factor for fulvestrant-related AEs. The co-administration of fulvestrant with CYP3A4 enzyme inhibitors did not show statistically significant correlation with the occurrence of severe AEs. Co-administration of drugs with extremely high protein binding (>/= 98%) may increase the risk of severe adverse reactions of fulvestrant. Meanwhile, age (60-74 years) may reduce the risk of severe AEs of fulvestrant. However, further clinical research is still needed to explore and verify whether there is interaction between fulvestrant and drugs with high protein binding through more clinical studies. |
|---|
| ジャーナル名 | Scientific reports |
|---|
| Pubmed追加日 | 2024/5/19 |
|---|
| 投稿者 | Yin, Guisen; Song, Guiling; Xue, Shuyi; Liu, Fen |
|---|
| 組織名 | Department of Pharmacy, Yantai Hospital of Traditional Chinese Medicine,;YantaiShandong, 264000, China.;Department of Chemical Medicine, Yantai Center for Food and Drug Control,;YantaiShandong, 264003, China.;Department of Pharmacy, Qingdao Central Hospital, University of Health and;Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao, 266042,;Shandong, China.;Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of;Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410011,;Hunan, China. liufen@hnca.org.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38762547/ |
|---|
